FiercePharmaOriginal article
{"a":[{"_":"ESC: Cytokinetics delves deeper on ‘huge’ Myqorzo readout, fueling cardiomyopathy expansion bid ","$":{"href":"/pharma/esc-2026-cytokinetics-delves-deeper-huge-myqorzo-readout-fueling-cardiomyopathy-expansion","hreflang":"en"}}]}
Data ReadoutpositiveMyqorzoPositive
AI Analysis
Summary
Cytokinetics presented data showing Myqorzo achieved significant, clinically meaningful benefits in patients with non-obstructive hypertrophic cardiomyopathy at ESC 2026, potentially doubling the drug's addressable patient population.
Outcome Details
Myqorzo demonstrated significant, clinically meaningful benefits in patients with non-obstructive hypertrophic cardiomyopathy
Importance:7/10
Sentiment:
0.75
cardiac myosin inhibitorrare diseasehypertrophic cardiomyopathyESC 2026expansion indication
Read the original article
Published by FiercePharma on August 27, 2026 2:47 PM